Home » Covid, the Moderna vaccine 95 percent effective in preventing hospitalizations

Covid, the Moderna vaccine 95 percent effective in preventing hospitalizations

by admin

Modern superstar. In fact, according to new American studies, not only do vaccines continue to demonstrate a very high protection against Covid-19 and its variants, but Moderna seems to have even greater effectiveness. The study is signed by Shaun Grannis, vice president of the Regenstrief Institute for data and analysis and professor of medicine at Indiana University School of Medicine.

Covid, the importance of vaccine efficacy studies

by Jacopo Vergari


More than 32,000 emergency or hospital access cases were analyzed in nine states between June, July and August 2021, when the Delta variant became the predominant strain. The study was carried out thanks to data from the Centers for Disease Control and Prevention (CDC) ‘s VISION Network (seven organizations that contribute and analyze data from US health systems to learn more about the effectiveness of the COVID-19 vaccine).

The results showed that unvaccinated individuals were 5-7 times more likely to need treatment in the emergency room or directly in hospital. But not only. The study found a difference in the effectiveness of vaccines. Moderna was 95 percent effective in preventing hospitalization of adults aged 18 and over, Pfizer was 80 percent and Johnson & Johnson 60 percent. The effectiveness of the vaccine becomes less in people aged 75 and over. As for emergency admissions, the analysis showed that Moderna was 92 percent effective, Pfizer 77 percent, and Johnson & Johnson 65 percent.

Covid: towards a single vaccine against Coronavirus and flu

See also  involvement of pharmacies in issuing the "green pass"

by Viola Rita


Research from the University of Virginia School of Medicine published in JAMA then compares the antibody response generated by Pfizer and Moderna vaccines. The researchers note that both have worked very well on millions of people but a slightly higher level of antibody levels emerges in the Moderna vaccine recipients. These kinds of studies are used to understand whether measuring antibody levels can be a good marker of vaccine protection and also whether a vaccine can be more effective for certain demographic groups.

As noted, Pfizer and Moderna both use mRNA to teach the immune system how to defend against Covid’s spike protein. However, the formulations are different: Moderna uses more mRNA than Pfizer. The scientists examined the blood of 167 university employees, collected a week to a month after the second dose: 79 of them received Pfizer and 88 Moderna. The median age was 42, 38% were in their 50s and over and, in total, 72% were women.

Covid, the vaccine works even if there are no adverse reactions

by Noemi Penna


Analyzes showed that Moderna produced more antibodies in the blood after the second dose than Pfizer: 68.5 micrograms per milliliter (µg / mL) versus 45.9. People over the age of 50 vaccinated with Pfizer produced fewer antibodies in the second dose than younger people, while there was no difference in antibody levels in older adults versus younger people who received Moderna.

Obviously, more studies are needed: there is no certainty that antibodies can be used to evaluate clinical protection against Covid-19.

See also  Coronavirus around the world. Moderna CEO: "Less effective vaccines against Omicron". First case in Japan

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy